Dr. James Lewis: The new approach to still centering around p16 immunohistochemistry as the “across the board” test for classification. However, we are trying to be more cautious – in a word ...

“Why you can trust Digital Trends – We have a 20-year history of testing, reviewing, and rating products, services and apps to help you make a sound buying decision. Find out more about how we ...

Methods: Formalin fixed paraffin embedded tissue blocks from 110 patients with a diagnosis of ESCC were tested for p16 immunohistochemistry. The analysis of the data was done using Stata version 17.0.

Methods: Formalin fixed paraffin embedded tissue blocks from 110 patients with a diagnosis of ESCC were tested for p16 immunohistochemistry. The analysis of the data was done using Stata version 17.0.

Drs. Fatme Ghandour and Sameer Al Diffalha presented the poster, "P16 Immunohistochemistry Is Helpful in Differentiating Grade 3 Neuroendocrine Tumors from Neuroendocrine Carcinomas." On Wednesday, ...

To the best of our knowledge, this is the first study conducted in Saudi Arabia to evaluate the expression of p16 through immunohistochemistry (IHC) in breast carcinoma. The recipient blocks were ...

The present study aims to examine the association between p16 expression and clinicopathological factors in breast cancer using immunohistochemistry staining. The study utilised 475 prospectively ...

P16 immunohistochemistry was performed on the baseline cervical biopsy with a positive result defined as strong abnormal nuclear expression in a continuous block segment of cells (at least 10–20 cells ...

PSCC is a rare cancer, with approximately half of all cases related to HPV. While HPV and p16 IHC testing have proven their prognostic value for oropharyngeal cancer, this is not yet established for ...

Oropharyngeal cancer patients who have discordant p16 and HPV status have worse prognosis than patients who have p16+/HPV+ disease, a study suggests. Classifying patients with oropharyngeal cancer ...

"Classification of patients with oropharyngeal cancer based on p16+ immunohistochemistry alone is inadequate in a trial setting," the authors conclude, "and is likely to be insufficient in routine ...